Clinical Gallery
Cartesion Prime SP
Clinical PET Innovations
New care pathways using PET-CT.
The expectations of Digital TOF PET-CT are to see measurable improvements in System Utilization and Clinical or Operational benefits for your healthcare facility and nuclear medicine department. Canon believes with the launch of Cartesion Prime SP we have made some unique design choices that can quite possibly make those expectations a reality.
Head &Neck
Brain, NeuraCeq (F-18 Florbetaben) Imaging1
Cartesion Prime SP
F-18 Florbetaben brain imaging acquired on Cartesion Prime SP Digital PET-CT system. These scans may be used to assess Alzheimer's disease.
NeuroQ™
NeuroQ by Syntermed is an optional application integrated into Vitrea® Advanced Visualization.NeuroQ is used to access neurodegenerative processes and underlying symptoms of cognitive and movement disorders.
| PET | |
| Injected Dose | 7.4 mCi F-18 Florbetaben |
| Uptake Time | 47 min |
| Patient Height | 6’ |
| Patient BMI | 26.8 |
| Time per Bed | 15 min |
| Total Scan Time | 15 min |
| TOF | ON |
| Iterations/Subsets | 5/24 |
| Post-Filter | GF 4.0 mm |
1 Images processed by NeuroQ application integrated into Vitrea® Advanced Visualization.
Clinical results are the experience of the facility. Results may vary due to clinical setting, patient presentation and other factors.
Head &Neck
FDG Neuro PET Imaging
Cartesion Prime SP
Dementia and or amyloid plaques are hallmarks of Alzheimer's disease.
More than 6,000,0001 Americans, most of them age 65 or older, may have dementia caused by Alzheimer's.
View Scan Parameters| PET | |
| Injected Dose | 7.7 mCi FDG |
| Uptake Time | 60 min |
| Patient BMI | - |
| Time Per Bed | 7.5 min |
| Total Scan Time | 7.5 min |
| Recon | 3D OSEM |
| TOF | ON |
| PSF | ON |
| Iterations/Subsets | 5/24 |
| Post-filter | Gaussian 4.0 mm |
1Alz.org
Clinical results may vary due to clinical setting, patient presentation and other factors.
